Benedikt Rumpf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Benedikt Rumpf has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Starlinger
Department of Surgery, Mayo Clinic , Rochester, MN 55905
6 shared publications - Jonas Santol
Department of Surgery, HPB Center, Vienna Health Network, Clinic Favoriten and Sigmund Freud Private University, Vienna, Austria
4 shared publications Anna S. Jankoschek
Medical University of Vienna, Vienna, Austria
3 shared publications- David Pereyra
Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA; Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria
3 shared publications - Gregor Ortmayr
Center for Cancer Research, Medical University of Vienna, Vienna, Austria
3 shared publications Joel Probst
Department of Surgery, HPB Center, Vienna Health Network, Clinic Favoriten and Sigmund Freud Private University, Vienna, Austria; Medical University of Vienna, Vienna, Austria
3 shared publications
Latest Publications
- Open Access
- 17 September 2025
- Published by Elsevier in EBioMedicine
- Vol. 120, 105928
PNPLA3 polymorphism worsens chemotherapy associated liver injury and affects overall survival in colorectal cancer patients with liver metastasis undergoing hepatic resection
- 17 September 2025
- Published by Elsevier in EBioMedicine
- Vol. 120, 105928
Open AccessPNPLA3 polymorphism worsens chemotherapy associated liver injury and affects overall survival in colorectal cancer patients with liver metastasis undergoing hepatic resection
- Open Access
- 4 October 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (4) , 101226
Soluble TREM2 reflects liver fibrosis status and predicts postoperative liver dysfunction after liver surgery
- 4 October 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (4) , 101226
Open AccessSoluble TREM2 reflects liver fibrosis status and predicts postoperative liver dysfunction after liver surgery
- Open Access
- 31 August 2022
- Published by Elsevier in The Lancet Digital Health
- Vol. 4 (10) , e727-e737
Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study
- 31 August 2022
- Published by Elsevier in The Lancet Digital Health
- Vol. 4 (10) , e727-e737
Open AccessPredictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study
- Open Access
- 5 October 2021
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (14) , 2807-2820
Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study
Anticoagulation was associated with improved survival of hospitalized coronavirus disease 2019 (COVID-19) patients in large-scale studies. Yet, the development of COVID-19-associated coagulopathy (CAC) and the mechanism responsible for improved survival of anticoagulated patients with COVID-19 remain largely elusive. This investigation aimed to explore the effects of anticoagulation and low-molecular-weight heparin (LMWH) in particular on patient outcome, CAC development, thromboinflammation, cell death, and viral persistence. Data of 586 hospitalized COVID-19 patients from three different regions of Austria were evaluated retrospectively. Of these, 419 (71.5%) patients received LMWH and 62 (10.5%) received non-vitamin-K oral anticoagulants (NOACs) during hospitalization. Plasma was collected at different time points in a subset of 106 patients in order to evaluate markers of thromboinflammation (H3Cit-DNA) and the cell death marker cell-free DNA (cfDNA). Use of LMWH was associated with improved survival upon multivariable Cox regression (hazard ratio = 0.561, 95% confidence interval: 0.348–0.906). Interestingly, neither LMWH nor NOAC was associated with attenuation of D-dimer increase over time, or thromboinflammation. In contrast, anticoagulation was associated with a decrease in cfDNA during hospitalization, and curtailed viral persistence was observed in patients using LMWH leading to a 4-day reduction of virus positivity upon quantitative polymerase chain reaction [13 (interquartile range: 6–24) vs. 9 (interquartile range: 5–16) days, P = 0.009]. Time courses of haemostatic and thromboinflammatory biomarkers were similar in patients with and without LMWH, indicating either no effects of LMWH on haemostasis or that LMWH reduced hypercoagulability to levels of patients without LMWH. Nonetheless, anticoagulation with LMWH was associated with reduced mortality, improved markers of cell death, and curtailed viral persistence, indicating potential beneficial effects of LMWH beyond haemostasis, which encourages use of LMWH in COVID-19 patients without contraindications.
- 5 October 2021
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (14) , 2807-2820
Open AccessLow-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study
Anticoagulation was associated with improved survival of hospitalized coronavirus disease 2019 (COVID-19) patients in large-scale studies. Yet, the development of COVID-19-associated coagulopathy (CAC) and the mechanism responsible for improved survival of anticoagulated patients with COVID-19 remain largely elusive. This investigation aimed to explore the effects of anticoagulation and low-molecular-weight heparin (LMWH) in particular on patient outcome, CAC development, thromboinflammation, cell death, and viral persistence. Data of 586 hospitalized COVID-19 patients from three different regions of Austria were evaluated retrospectively. Of these, 419 (71.5%) patients received LMWH and 62 (10.5%) received non-vitamin-K oral anticoagulants (NOACs) during hospitalization. Plasma was collected at different time points in a subset of 106 patients in order to evaluate markers of thromboinflammation (H3Cit-DNA) and the cell death marker cell-free DNA (cfDNA). Use of LMWH was associated with improved survival upon multivariable Cox regression (hazard ratio = 0.561, 95% confidence interval: 0.348–0.906). Interestingly, neither LMWH nor NOAC was associated with attenuation of D-dimer increase over time, or thromboinflammation. In contrast, anticoagulation was associated with a decrease in cfDNA during hospitalization, and curtailed viral persistence was observed in patients using LMWH leading to a 4-day reduction of virus positivity upon quantitative polymerase chain reaction [13 (interquartile range: 6–24) vs. 9 (interquartile range: 5–16) days, P = 0.009]. Time courses of haemostatic and thromboinflammatory biomarkers were similar in patients with and without LMWH, indicating either no effects of LMWH on haemostasis or that LMWH reduced hypercoagulability to levels of patients without LMWH. Nonetheless, anticoagulation with LMWH was associated with reduced mortality, improved markers of cell death, and curtailed viral persistence, indicating potential beneficial effects of LMWH beyond haemostasis, which encourages use of LMWH in COVID-19 patients without contraindications.
- 1 October 2019
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 229 (4) , e147-E147
Impairment of Fibrinogen Deposition during Early Liver Regeneration Leads to Adverse Outcome after Liver Resection in Humans
- 1 October 2019
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 229 (4) , e147-E147
Impairment of Fibrinogen Deposition during Early Liver Regeneration Leads to Adverse Outcome after Liver Resection in Humans
- Open Access
- 1 October 2019
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 229 (4) , e156-E156
Von Willebrand Factor Antigen Facilitates Long-Term Risk Stratification in Patients Undergoing Liver Resection
- 1 October 2019
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 229 (4) , e156-E156
Open AccessVon Willebrand Factor Antigen Facilitates Long-Term Risk Stratification in Patients Undergoing Liver Resection